- Home
- XBIO vs GRI Comparison
XBIO vs GRI Comparison
Compare XBIO & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- GRI
- Stock Information
- Founded
- XBIO N/A
- GRI 2018
- Country
- XBIO United States
- GRI United States
- Employees
- XBIO N/A
- GRI N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- XBIO Health Care
- GRI Health Care
- Exchange
- XBIO Nasdaq
- GRI Nasdaq
- Market Cap
- XBIO 6.3M
- GRI 5.6M
- IPO Year
- XBIO N/A
- GRI N/A
- Fundamental
- Price
- XBIO $4.03
- GRI $0.42
- Analyst Decision
- XBIO Hold
- GRI Strong Buy
- Analyst Count
- XBIO 1
- GRI 2
- Target Price
- XBIO N/A
- GRI $11.50
- AVG Volume (30 Days)
- XBIO 4.8K
- GRI 181.8K
- Earning Date
- XBIO 03-20-2025
- GRI 03-27-2025
- Dividend Yield
- XBIO N/A
- GRI N/A
- EPS Growth
- XBIO N/A
- GRI N/A
- EPS
- XBIO N/A
- GRI N/A
- Revenue
- XBIO $2,523,427.00
- GRI N/A
- Revenue This Year
- XBIO N/A
- GRI N/A
- Revenue Next Year
- XBIO N/A
- GRI N/A
- P/E Ratio
- XBIO N/A
- GRI N/A
- Revenue Growth
- XBIO 7.15
- GRI N/A
- 52 Week Low
- XBIO $2.78
- GRI $0.30
- 52 Week High
- XBIO $5.20
- GRI $12.31
- Technical
- Relative Strength Index (RSI)
- XBIO 45.61
- GRI 28.18
- Support Level
- XBIO $3.91
- GRI $0.43
- Resistance Level
- XBIO $4.24
- GRI $0.60
- Average True Range (ATR)
- XBIO 0.17
- GRI 0.06
- MACD
- XBIO -0.01
- GRI -0.00
- Stochastic Oscillator
- XBIO 28.93
- GRI 10.91
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.